Xencor Inc (FRA:XE9)
€ 23.4 0.4 (1.74%) Market Cap: 1.63 Bil Enterprise Value: 1.19 Bil PE Ratio: 0 PB Ratio: 2.35 GF Score: 59/100

Xencor Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript

Feb 24, 2021 / 08:00PM GMT
Release Date Price: €40 (+2.56%)
Wei Ji Chang
SVB Leerink LLC, Research Division - MD of Emerging Oncology & Senior Research Analyst

Hello, everyone. Thanks for joining us. My name is Jonathan Chang. I'm part of the SVB Leerink equity research team. It's my pleasure to host the management team of Xencor, and we have with us today, President and CEO, Bassil Dahiyat. And for the investors joining us, feel free to submit questions or e-mail them to me at [email protected]. And with that, let's get started.

Bassil, would you please briefly introduce the company?

Bassil I. Dahiyat
Xencor, Inc. - Co-Founder, CEO, President & Director

Sure, and thanks very much, Jonathan, for the opportunity to participate in the Leerink conference today.

Xencor is a protein engineering company. We engineer antibodies and other protein molecules to optimize their functions, often immunologic functions, to make them into drugs. We've built a platform based on this protein engineering approach that's centered on a suite of engineered modules, Fc domains, that are the bottom

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot